New Drug Shows Significant Hemoglobin Improvement for Rare Autoimmune Blood Disorder

Johnson & Johnson has released comprehensive results from its Phase 2/3 ENERGY study, demonstrating that IMAAVY® (nipocalimab-aahu) achieved a statistically significant and rapid hemoglobin response in patients with warm autoimmune hemolytic anemia (wAIHA). This condition is a rare, life-threatening disorder currently lacking FDA-approved therapies. The positive findings are being presented at the European Hematology Association Congress.